Corbus Pharmaceuticals Holdings Inc. [CRBP] stock Downgrade by ROTH Capital analyst, price target now $3

Corbus Pharmaceuticals Holdings Inc. [NASDAQ: CRBP] slipped around -0.02 points on Friday, while shares priced at $0.13 at the close of the session, down -13.35%. The company report on November 10, 2022 that Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

CRB-601 is a potent and selective anti-αvβ8 integrin monoclonal antibody designed to block the activation of latent TGFβ selectively within the tumor microenvironment.

CRB-601 significantly inhibits tumor growth as a single agent and enhances the efficacy of anti-PD-1 immunotherapy in checkpoint inhibitor (CPI) sensitive and CPI-resistant tumor models.

Corbus Pharmaceuticals Holdings Inc. stock is now -78.71% down from its year-to-date (YTD) trading value. CRBP Stock saw the intraday high of $0.1511 and lowest of $0.108 per share. The company’s 52-week high price is 0.87, which means current price is +31.10% above from all time high which was touched on 01/03/22.

Compared to the average trading volume of 4.82M shares, CRBP reached a trading volume of 13259077 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Corbus Pharmaceuticals Holdings Inc. [CRBP]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRBP shares is $3.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRBP stock is a recommendation set at 2.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

ROTH Capital have made an estimate for Corbus Pharmaceuticals Holdings Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on September 08, 2020. The new note on the price target was released on September 08, 2020, representing the official price target for Corbus Pharmaceuticals Holdings Inc. stock. Previously, the target price had yet another drop from $18 to $2.50, while Jefferies kept a Hold rating on CRBP stock.

The Average True Range (ATR) for Corbus Pharmaceuticals Holdings Inc. is set at 0.02 The Price to Book ratio for the last quarter was 0.40, with the Price to Cash per share for the same quarter was set at 0.46.

How has CRBP stock performed recently?

Corbus Pharmaceuticals Holdings Inc. [CRBP] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.00. With this latest performance, CRBP shares gained by 3.64% in over the last four-week period, additionally sinking by -56.90% over the last 6 months – not to mention a drop of -84.06% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRBP stock in for the last two-week period is set at 49.43, with the RSI for the last a single of trading hit 49.57, and the three-weeks RSI is set at 48.34 for Corbus Pharmaceuticals Holdings Inc. [CRBP]. The present Moving Average for the last 50 days of trading for this stock 0.1364, while it was recorded at 0.1436 for the last single week of trading, and 0.2643 for the last 200 days.

Corbus Pharmaceuticals Holdings Inc. [CRBP]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Corbus Pharmaceuticals Holdings Inc. [CRBP] shares currently have an operating margin of -6350.09 and a Gross Margin at -85.92. Corbus Pharmaceuticals Holdings Inc.’s Net Margin is presently recorded at -5176.38.

Return on Equity for this stock declined to -79.80, with Return on Assets sitting at -43.46.

Corbus Pharmaceuticals Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.90 and a Current Ratio set at 3.90.

Insider trade positions for Corbus Pharmaceuticals Holdings Inc. [CRBP]

There are presently around $3 million, or 19.00% of CRBP stock, in the hands of institutional investors. The top three institutional holders of CRBP stocks are: KNOLL CAPITAL MANAGEMENT, LLC with ownership of 5,045,870, which is approximately 0% of the company’s market cap and around 0.30% of the total institutional ownership; ETF MANAGERS GROUP, LLC, holding 4,710,319 shares of the stock with an approximate value of $0.62 million in CRBP stocks shares; and VANGUARD GROUP INC, currently with $0.53 million in CRBP stock with ownership of nearly -5.718% of the company’s market capitalization.

Positions in Corbus Pharmaceuticals Holdings Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 19 institutional holders increased their position in Corbus Pharmaceuticals Holdings Inc. [NASDAQ:CRBP] by around 608,016 shares. Additionally, 29 investors decreased positions by around 9,124,276 shares, while 31 investors held positions by with 13,637,458 shares. The mentioned changes placed institutional holdings at 23,369,750 shares, according to the latest SEC report filing. CRBP stock had 8 new institutional investments in for a total of 432,809 shares, while 14 institutional investors sold positions of 1,082,337 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here